TORONTO, July 17, 2026
Arch Biopartners Inc. has taken a significant step toward advancing its pre-Investigational New Drug (pre-IND) chronic kidney disease (CKD) program by engaging a U.S.-based bioengineering laboratory to accelerate research focused on IL-32, an emerging therapeutic target for diabetic kidney disease (DKD). The selected laboratory will conduct specialized preclinical studies designed to generate proprietary scientific data, strengthen the company’s intellectual property portfolio, and support future patent filings covering IL-32 drug candidates and method-of-use claims. The collaboration represents the next phase of development following the identification of IL-32 as a promising therapeutic target capable of addressing inflammation and kidney injury associated with diabetic kidney disease. According to Chief Executive Officer Richard Muruve, the agreement is expected to accelerate research activities while creating a valuable proprietary dataset that supports both the company’s long-term drug development strategy and potential future partnership opportunities. The initiative highlights Arch Biopartners’ commitment to expanding innovative therapies for chronic kidney disease, an area with substantial unmet medical need and growing global healthcare impact.
IL-32 Research Strengthens Scientific Foundation for CKD Therapy
The company’s CKD development platform is primarily focused on diabetic kidney disease, one of the leading causes of kidney failure worldwide and a major contributor to end-stage renal disease. Arch’s research program is supported by findings from human kidney tissue analyses, disease models, and peer-reviewed scientific studies demonstrating a strong association between IL-32, lipid droplet biology, chronic inflammation, and tubular kidney injury. Additional evidence published in Inflammation Research during February 2026 further reinforced IL-32’s role in metabolic stress, persistent inflammatory responses, and progressive kidney damage, providing a strong scientific rationale for developing therapies that specifically target this inflammatory pathway. By collaborating with an experienced bioengineering laboratory possessing expertise in advanced drug development research, Arch aims to generate robust preclinical evidence required for future regulatory submissions while enhancing the commercial value of its proprietary CKD platform. The research also strengthens the company’s broader objective of developing next-generation therapies capable of slowing disease progression in patients suffering from diabetic kidney disease.
Pipeline Expansion and Corporate Update Support Long-Term Growth
Alongside the research announcement, Arch Biopartners provided a corporate update regarding its ongoing market-making agreement with Red Cloud Securities Inc. (RCSI), which assumed responsibility for the engagement after the market-making team transitioned from Research Capital Corporation in April 2022. Under the month-to-month agreement, RCSI receives a monthly fee of C$5,000 to provide market-making services on the TSX Venture Exchange, helping maintain an orderly market, improve trading liquidity, and reduce share price volatility using its own capital without receiving shares or performance-based compensation. The agreement remains subject to TSXV approval. Beyond its IL-32 CKD platform, Arch continues advancing a diversified kidney disease pipeline that includes the LSALT peptide, currently in a Phase II clinical trial for cardiac surgery-associated acute kidney injury (AKI), and Cilastatin, a repurposed therapy also in a Phase II trial targeting toxin-induced AKI. With more than 800 million people worldwide affected by chronic kidney disease, Arch Biopartners is positioning its innovative pipeline to address both acute and chronic kidney disorders, while ongoing Phase II studies continue enrolling patients across Canadian clinical sites with additional North American expansion planned.
Advertisement
Arch Biopartners Positions IL-32 Platform for Future Clinical Development
The engagement of a specialized U.S. laboratory marks an important milestone in the evolution of Arch Biopartners’ IL-32 chronic kidney disease program, moving the project closer to future IND-enabling studies and potential clinical development. By investing in proprietary preclinical research, expanding intellectual property protection, and strengthening scientific validation around IL-32 as a therapeutic target, the company is building a differentiated platform aimed at addressing one of the world’s fastest-growing chronic diseases. Combined with its active Phase II acute kidney injury programs, Arch continues to broaden its kidney disease portfolio through mechanism-based therapeutic approaches designed to reduce inflammation, protect kidney tissue, and improve long-term patient outcomes. The latest research collaboration reflects the company’s strategy of advancing innovative kidney therapies while creating opportunities for future regulatory progress, strategic partnerships, and commercial development..
Source: Arch Biopartners press release
